Chronic Reductions in Serotonin Transporter Function Prevent 5-HT1B-Induced Behavioral Effects in Mice

Biological Psychiatry

Volumn 65, Issue 5, 2009, Pages 401-408

  Shanahan, Nancy A ^a   Holick Pierz, Kerri A ^b   Masten, Virginia L ^c   Waeber, Christian ^d   Ansorge, Mark ^b   Gingrich, Jay A ^b   Geyer, Mark A ^c   Hen, Rene ^b   Dulawa, Stephanie C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

5 HT1B receptor; 5 HTT; antidepressant; OCD; PPI

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; FLUOXETINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; N,N BIS(3 HYDROXYPHENETHYL)PROPYLAMINE; SEROTONIN 1B RECEPTOR; SEROTONIN TRANSPORTER; SULFUR 35;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DRUG BINDING; GLOBUS PALLIDUS; LOCOMOTION; MOUSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PREPULSE INHIBITION; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; FEMALE; FLUOXETINE; GLOBUS PALLIDUS; INDOLES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MOTOR ACTIVITY; OXADIAZOLES; PIPERAZINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STARTLE REACTION; SUBSTANTIA NIGRA;

EID: 59249093767     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.09.026     Document Type: Article

References (57)

1. Sanders A.R., Duan J., and Gejman P.V. DNA variation and psychopharmacology of the human serotonin receptor 1B (HTR1B) gene. Pharmacogenomics 3 (2002) 745-762
2. Mundo E., Richter M.A., Sam F., Macciardi F., and Kennedy J.L. Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder?. Am J Psychiatry 157 (2000) 1160-1161
3. Stein D.J., Van Heerden B., Wessels C.J., Van Kradenburg J., Warwick J., and Wasserman H.J. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: Investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry 23 (1999) 1079-1099
4. Gross-Isseroff R., Cohen R., Sasson Y., Voet H., and Zohar J. Serotonergic dissection of obsessive compulsive symptoms: A challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 50 (2004) 200-205
5. Koran L.M., Pallanti S., and Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol 11 (2001) 169-172
6. Zohar J., Kennedy J.L., Hollander E., and Koran L.M. Serotonin-1D hypothesis of obsessive-compulsive disorder: An update. J Clin Psychiatry 65 suppl 14 (2004) 18-21
7. Pian K.L., Westenberg H.G., van Megen H.J., and den Boer J.A. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology (Berl) 140 (1998) 365-370
8. Boshuisen M.L., and den Boer J.A. Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder. Psychopharmacology (Berl) 152 (2000) 74-79
9. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78 (2006) 815-826
10. Wendland J.R., Moya P.R., Kruse M.R., Ren-Patterson R.F., Jensen C.L., Timpano K.R., and Murphy D.L. A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. Hum Mol Genet 17 (2008) 717-723
11. Ozaki N., Goldman D., Kaye W.H., Plotnicov K., Greenberg B.D., Lappalainen J., et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 8 (2003) 895 933-896
12. Delorme R., Betancur C., Wagner M., Krebs M.O., Gorwood P., Pearl P., et al. Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. Mol Psychiatry 10 (2005) 1059-1061
13. Hollander E., and Pallanti S. Current and experimental therapeutics of OCD. In: Davis K., Charney D., Coyle J., and Nemeroff C. (Eds). Neuropsychopharmacology: The Fifth Generation of Progress (2002), Lippincott Williams & Wilkins, Philadelphia 1648-1665
14. Swerdlow N.R., Benbow C.H., Zisook S., Geyer M.A., and Braff D.L. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry 33 (1993) 298-301
15. Hoenig K., Hochrein A., Quednow B.B., Maier W., and Wagner M. Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder. Biol Psychiatry 57 (2005) 1153-1158
16. Graham F.K. Presidential Address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology 12 (1975) 238-248
17. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl) 156 (2001) 117-154
18. Swerdlow N.R., Caine S.B., Braff D.L., and Geyer M.A. The neural substrates of sensorimotor gating of the startle reflex: A review of recent findings and their implications. J Psychopharmacol 6 (1992) 176-190
19. Bakshi V.P., and Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci 18 (1998) 8394-8401
20. Bakshi V.P., and Geyer M.A. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther 283 (1997) 666-674
21. Dulawa S.C., and Geyer M.A. Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology 39 (2000) 2170-2179
22. Dulawa S.C., Hen R., Scearce-Levie K., and Geyer M.A. 5-HT1B receptor modulation of prepulse inhibition: Recent findings in wild-type and 5-HT1B knockout mice. Ann N Y Acad Sci 861 (1998) 79-84
23. Sipes T.A., and Geyer M.A. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 33 (1994) 441-448
24. Cheetham S.C., and Heal D.J. Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor. Br J Pharmacol 110 (1993) 1621-1629
25. Chaouloff F., Courvoisier H., Moisan M.P., and Mormede P. GR 127935 reduces basal locomotor activity and prevents RU 24969-, but not D-amphetamine-induced hyperlocomotion, in the Wistar-Kyoto hyperactive (WKHA) rat. Psychopharmacology (Berl) 141 (1999) 326-331
26. Rempel N.L., Callaway C.W., and Geyer M.A. Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 8 (1993) 201-211
27. Oberlander C., Blaquiere B., and Pujol J.F. Distinct functions for dopamine and serotonin in locomotor behaviour: Evidence using the 5-HT1 agonist RU 24969 in globus pallidus-lesioned rats. Neurosci Lett 67 (1986) 113-118
28. Peroutka S.J. Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex. J Neurochem 47 (1986) 529-540
29. Lira A., Zhou M., Castanon N., Ansorge M.S., Gordon J.A., Francis J.H., et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry 54 (2003) 960-971
30. Dulawa S.C., Holick K.A., Gundersen B., and Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29 (2004) 1321-1330
31. Oksenberg D., Marsters S.A., O'Dowd B.F., Jin H., Havlik S., Peroutka S.J., and Ashkenazi A. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360 (1992) 161-163
32. Parker E.M., Grisel D.A., Iben L.G., and Shapiro R.A. A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine1B receptors. J Neurochem 60 (1993) 380-383
33. Paulus M.P., and Geyer M.A. Quantitative assessment of the microstructure of rat behavior: I, f(d), the extension of the scaling hypothesis. Psychopharmacology (Berl) 113 (1993) 177-186
34. Gordon C.T., State R.C., Nelson J.E., Hamburger S.D., and Rapoport J.L. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50 (1993) 441-447
35. McDougle C.J. Current and emerging therapeutics of autistic disorder and related pervasive developmental disorders. In: Davis K., Charney D., Coyle J., and Nemeroff C. (Eds). Neuropsychopharmacology: The Fifth Generation of Progress (2002), Lippincott Williams & Wilkins, Philadelphia 566-577
36. Hollander E., Novotny S., Allen A., Aronowitz B., Cartwright C., and DeCaria C. The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology 22 (2000) 163-167
37. Novotny S., Hollander E., Allen A., Mosovich S., Aronowitz B., Cartwright C., et al. Increased growth hormone response to sumatriptan challenge in adult autistic disorders. Psychiatry Res 94 (2000) 173-177
38. McAlonan G.M., Daly E., Kumari V., Critchley H.D., van Amelsvoort T., Suckling J., et al. Brain anatomy and sensorimotor gating in Asperger's syndrome. Brain 125 (2002) 1594-1606
39. Dulawa S.C., Hen R., Scearce-Levie K., and Geyer M.A. Serotonin1B receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin1B knockout mice. Psychopharmacology (Berl) 132 (1997) 125-134
40. Callaway C.W., and Geyer M.A. Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist. J Pharmacol Exp Ther 263 (1992) 318-326
41. Quednow B.B., Kuhn K.U., Stelzenmuelle R., Hoenig K., Maier W., and Wagner M. Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression. Psychopharmacology (Berl) 175 (2004) 399-406
42. Pouzet B., Andersen M.P., and Hogg S. Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats. Psychopharmacology (Berl) 178 (2005) 9-16
43. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156 (2001) 234-258
44. Gothert M., Hamon M., Barann M., Bonisch H., Gozlan H., Laguzzi R., et al. 5-HT3 receptor antagonism by anpirtoline, a mixed 5-HT1 receptor agonist/5-HT3 receptor antagonist. Br J Pharmacol 114 (1995) 269-274
45. Paulus M.P., Dulawa S.C., Ralph R.J., and Mark A.G. Behavioral organization is independent of locomotor activity in 129 and C57 mouse strains. Brain Res 835 (1999) 27-36
46. Saudou F., Amara D.A., Dierich A., LeMeur M., Ramboz S., Segu L., et al. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science 265 (1994) 1875-1878
47. Fletcher P.J., Sinyard J., and Higgins G.A. The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists. Psychopharmacology (Berl) 187 (2006) 515-525
48. Fabre V., Beaufour C., Evrard A., Rioux A., Hanoun N., Lesch K.P., et al. Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci 12 (2000) 2299-2310
49. Pejchal T., Foley M.A., Kosofsky B.E., and Waeber C. Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography. Br J Pharmacol 135 (2002) 1115-1122
50. Sprouse J., Reynolds L., Li X., Braselton J., and Schmidt A. 8-OH-DPAT as a 5-HT7 agonist: Phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology 46 (2004) 52-62
51. Johnson S.W., Mercuri N.B., and North R.A. 5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons. J Neurosci 12 (1992) 2000-2006
52. Guan X.M., and McBride W.J. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull 23 (1989) 541-547
53. Higgins G.A., Jordan C.C., and Skingle M. Evidence that the unilateral activation of 5-HT1D receptors in the substantia nigra of the guinea-pig elicits contralateral rotation. Br J Pharmacol 102 (1991) 305-310
54. Delfs J.M., and Kelley A.E. The role of D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum. Neuroscience 39 (1990) 59-67
55. Koshikawa N., Aoki S., Tomiyama K., Maruyama Y., and Kobayashi M. Sulpiride injection into the dorsal striatum increases methamphetamine-induced gnawing in rats. Eur J Pharmacol 133 (1987) 119-125
56. Wisniecki A., Correa M., Arizzi M.N., Ishiwari K., and Salamone J.D. Motor effects of GABA(A) antagonism in globus pallidus: Studies of locomotion and tremulous jaw movements in rats. Psychopharmacology (Berl) 170 (2003) 140-149
57. Boulenguez P., Peters S.L., Mitchell S.N., Chauveau J., Gray J.A., and Joseph M.H. Dopamine release in the nucleus accumbens and latent inhibition in the rat following microinjections of a 5-HT1B agonist into the dorsal subiculum: Implications for schizophrenia. J Psychopharmacol 12 (1998) 258-267